# C4orf44 (P-19): sc-245782



The Power to Question

### **BACKGROUND**

Representing approximately 6% of the human genome, chromosome 4 contains nearly 900 genes. Notably, the Huntingtin gene, which is found to encode an expanded glutamine tract in cases of Huntington's disease, is on chromosome 4. FGFR-3 is also encoded on chromosome 4 and has been associated with thanatophoric dwarfism, achondroplasia, Muenke syndrome and bladder cancer. Chromosome 4 is also tied to Ellis-van Creveld syndrome, methylmalonic acidemia and polycystic kidney disease. Chromosome 4 reportedly contains the largest gene deserts (regions of the genome with no protein encoding genes) and has one of the two lowest recombination frequencies of the human chromosomes. The C4orf44 gene product has been provisionally designated C4orf44 pending further characterization.

### **REFERENCES**

- 1. Hillier, L.W., Graves, T.A., Fulton, R.S., Fulton, L.A., Pepin, K.H., Minx, P., Wagner-McPherson, C., Layman, D., Wylie, K., Sekhon, M., Becker, M.C., Fewell, G.A., et al. 2005. Generation and annotation of the DNA sequences of human chromosomes 2 and 4. Nature 434: 724-731.
- 2. Cowan, C.M. and Raymond, L.A. 2006. Selective neuronal degeneration in Huntington's disease. Curr. Top. Dev. Biol. 75:25-71.
- Chandler, R.J., Sloan, J., Fu, H., Tsai, M., Stabler, S., Allen, R., Kaestner, K.H., Kazazian, H.H. and Venditti, C.P. 2007. Metabolic phenotype of methylmalonic acidemia in mice and humans: the role of skeletal muscle. BMC Med. Genet. 8: 64
- Cunningham, M.L., Seto, M.L., Ratisoontorn, C., Heike, C.L. and Hing, A.V. 2007. Syndromic craniosynostosis: from history to hydrogen bonds. Orthod. Craniofac. Res. 10: 67-81.
- de Frutos, C.A., Vega, S., Manzanares, M., Flores, J.M., Huertas, H., Martínez-Frías, M.L. and Nieto, M.A. 2007. Snail1 is a transcriptional effector of FGFR3 signaling during chondrogenesis and achondroplasias. Dev. Cell 13: 872-883.
- Doherty, E.S., Lacbawan, F., Hadley, D.W., Brewer, C., Zalewski, C., Kim, H.J., Solomon, B., Rosenbaum, K., Domingo, D.L., Hart, T.C., Brooks, B.P., Immken, L., Lowry, R.B., Kimonis, V., et al. 2007. Muenke syndrome (FGFR3-related craniosynostosis): expansion of the phenotype and review of the literature. Am. J. Med. Genet. A 143: 3204-3215.
- Ruiz-Perez, V.L., Blair, H.J., Rodriguez-Andres, M.E., Blanco, M.J., Wilson, A., Liu, Y.N., Miles, C., Peters, H. and Goodship, J.A. 2007. Evc is a positive mediator of lhh-regulated bone growth that localises at the base of chondrocyte cilia. Development 134: 2903-2912.
- 8. Stack, E.C., Dedeoglu, A., Smith, K.M., Cormier, K., Kubilus, J.K., Bogdanov, M., Matson, W.R., Yang, L., Jenkins, B.G., Luthi-Carter, R., Kowall, N.W., Hersch, S.M., Beal, M.F. and Ferrante, R.J. 2007. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J. Neurosci. 27: 12908-12915.
- Versteegh, F.G., Buma, S.A., Costin, G., de Jong, W.C. and Hennekam, R.C. 2007. Growth hormone analysis and treatment in Ellis-van Creveld syndrome. Am. J. Med. Genet. A 143: 2113-2121.

#### **CHROMOSOMAL LOCATION**

Genetic locus: MSANTD1 (human) mapping to 4p16.3; Msantd1 (mouse) mapping to 5 B2.

### **SOURCE**

C4orf44 (P-19) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the N-terminus of C4orf44 of human origin.

### **PRODUCT**

Each vial contains 200  $\mu g$  lgG in 1.0 ml of PBS with <0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-245782 P, (100  $\mu$ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

### **APPLICATIONS**

C4orf44 (P-19) is recommended for detection of C4orf44 of human origin, A930005l04Rik of mouse origin and the corresponding rat homolog by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

C4orf44 (P-19) is also recommended for detection of C4orf44 in additional species, including equine, canine, bovine and porcine.

Suitable for use as control antibody for C4orf44 siRNA (h): sc-89001, A930005104Rik siRNA (m): sc-140692, C4orf44 shRNA Plasmid (h): sc-89001-SH, A930005104Rik shRNA Plasmid (m): sc-140692-SH, C4orf44 shRNA (h) Lentiviral Particles: sc-89001-V and A930005104Rik shRNA (m) Lentiviral Particles: sc-140692-V.

Molecular Weight of C4orf44: 32 kDa.

## **RECOMMENDED SECONDARY REAGENTS**

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

#### **STORAGE**

Store at 4° C, \*\*D0 NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

**Santa Cruz Biotechnology, Inc.** 1.800.457.3801 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**